<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="113417"><TitleDisplay>Comparison of Two Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure</TitleDisplay><TitleOfficial>Phase IV, Open-Label, Multicenter, Randomized, Controlled Trial: Comparison of Two Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Immunomodulator Failure</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">0169-12-WOMC</Identifier><Identifier type="NCT">NCT01802593</Identifier><Identifier type="Trial Acronym">WITHDRAW</Identifier></Identifiers><Indications><Indication id="84">Crohns disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>6-mercaptopurine</Name></Intervention><Intervention type="InterventionPrimary"><Name>azathioprine</Name></Intervention><Intervention type="InterventionPrimary"><Name>infliximab</Name><Drug id="6850">infliximab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>methotrexate</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6850">infliximab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1035934">Wolfson Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6850" type="Drug"><TargetEntity id="198460" type="siDrug">Infliximab</TargetEntity></SourceEntity><SourceEntity id="1035934" type="Company"><TargetEntity id="5035541636" type="organizationId">Edith Wolfson Medical Center</TargetEntity></SourceEntity><SourceEntity id="84" type="ciIndication"><TargetEntity id="K50" type="ICD10"></TargetEntity><TargetEntity id="10011401" type="MEDDRA"></TargetEntity><TargetEntity id="D003424" type="MeSH"></TargetEntity><TargetEntity id="-248155260" type="omicsDisease"></TargetEntity><TargetEntity id="395" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="381" type="Action"><TargetEntity id="663" type="Mechanism">TNF-alpha Antagonists</TargetEntity><TargetEntity id="1551" type="Mechanism">Anti-TNF-alpha</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1035934">Wolfson Medical Center</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="381">TNF alpha ligand inhibitor</Action><Action id="721">TNF binding agent</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2946">Analgesic</Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="128">Cell culture technique</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="652">Intra-articular formulation</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2013-02-28T00:00:00Z</DateStart><DateEnd type="actual">2015-12-30T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:39:06Z</DateChangeLast><DateAdded>2013-03-05T12:40:17Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Pediatric Gastroenterology and Nutrition Unit, The E. Wolfson MC, Tel-Aviv University, Holon, Israel</Affiliation><Name>Arie Levine, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Pediatric Gastroenterology and Nutrition Unit, The Hebrew University of Jerusalem, Shaare Zedek MC, Jerusalem, Israel</Affiliation><Name>Dan Turner, MD, PhD</Name></Contact><Contact type="Scientific contact"><Affiliation>Schneider Childrens Hospital</Affiliation><Name>Raanan Shamir, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Kaplan Medical Center</Affiliation><Name>Michal Kori, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Hadassah Medical Center</Affiliation><Name>Michael Wilshanski, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Meyer Childrens Hospital Rambam, Haifa, Israel</Affiliation><Name>Ron Shaoul, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Tel Aviv Medical Center</Affiliation><Name>Shlomi Cohen, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Sheba Medical Center</Affiliation><Name>Batia Weiss, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Afula Hospital</Affiliation><Name>Sarit Peleg, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Soroka Medical Center</Affiliation><Name>Baruch Yerushalmi, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Asaf Harofe Medical Center</Affiliation><Name>Efrat Broide, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Poriah Hospital</Affiliation><Name>Avi On, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Nazheret Hospital</Affiliation><Name>Hussein Chemali, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Carmel Hospital</Affiliation><Name>Aharon Lerner, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Crohns disease&lt;/li&gt;&lt;li&gt;Age 6 and 18 years (inclusive)&lt;/li&gt;&lt;li&gt;Active disease Pediatric Crohn's Disease Activity Index  (PCDAI)&amp;gt; 10, or any steroid dependence despite thiopurine use for &amp;gt; 10
             weeks&lt;/li&gt;&lt;li&gt;Naive to biologicals&lt;/li&gt;&lt;li&gt;Informed consent&lt;/li&gt;&lt;li&gt;C-reactive protein (CRP) &gt;/= 0.6 mg/dl&lt;/li&gt;&lt;li&gt;Negative tuberculosis (TB) test, negative Hepatitis B virus surface antigen (HBV- S Ag)&lt;/li&gt;&lt;li&gt;Use of immunomodulator at present or in past for at least 10 weeks&lt;/li&gt;&lt;li&gt;Negative stool culture, parasites and clostridium toxin current flare&lt;/li&gt;&lt;li&gt;Patients receiving corticosteroids may be included if the disease is active and CRP elevated&lt;/li&gt;&lt;li&gt;All other treatments such as 5ASA ,  must be discontinued immediately after the first infliximab infusion&lt;/li&gt;&lt;li&gt;Patients may receive an antihistamine prior to any infusion. Use of corticosteroid pretreatment is allowed only during the first two infusions (single infusion on day of infliximab), or if an infusion reaction has occurred&lt;/li&gt;&lt;li&gt;Partial enteral nutrition, accounting for&amp;lt; 50% of daily required calories, may be supplied as needed&lt;/li&gt;&lt;li&gt;Patients receiving antibiotics must cease use of antibiotics within the 14 days of receiving the first infusion&lt;/li&gt;&lt;li&gt;ESR &gt; 20 can be alternative if the CRP&amp;lt; 0.6&lt;/li&gt;&lt;li&gt;Negative stool culture, parasites and clostridium toxin current flare will examined only if the patient has diarrhea&lt;/li&gt;&lt;li&gt;Patients may be enrolled directly in to the Predict study , in which case duration of IMM is irrelevant , but patients must have received an IMM until week 2 as in the withdraw&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Intolerance to thiopurines/methotrexate&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Contraindication for any of the drugs&lt;/li&gt;&lt;li&gt;Leukopenia&amp;lt; 4000 or  absolute neutrophil count &amp;lt; 1200 on two consecutive tests
             during screening&lt;/li&gt;&lt;li&gt;Hepatocellular Liver disease ( ALT&amp;gt; 60 ) or cirrhosis&lt;/li&gt;&lt;li&gt;Renal Failure&lt;/li&gt;&lt;li&gt;Prior idiosyncratic  side effects with thiopurines ( pancreatitis etc)&lt;/li&gt;&lt;li&gt;Current abscess (&amp;lt; 14 days of antibiotics) or perforation of the bowel(&amp;lt; 14 days
             antibiotics)&lt;/li&gt;&lt;li&gt;Small bowel obstruction within the last 3 months&lt;/li&gt;&lt;li&gt;Fixed non inflammatory  stricture with predilatation with symptoms related to
             stricture&lt;/li&gt;&lt;li&gt;Complicated or heavily draining perianal fistula ( indolent non draining  or scant
             draining fistula are not exclusion criteria)&lt;/li&gt;&lt;li&gt;Prior treatment with&lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Previous malignancy&lt;/li&gt;&lt;li&gt;Toxic Megacolon&lt;/li&gt;&lt;li&gt;Sepsis&lt;/li&gt;&lt;li&gt;Surgery related to Crohn's disease  in previous 8 weeks&lt;/li&gt;&lt;li&gt;Positive Hepatitis B surface antigen or evidence for TB&lt;/li&gt;&lt;li&gt;Current bacterial infection&lt;/li&gt;&lt;li&gt;Inflammatory bowel disease (IBD) unclassified&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Complete or partial LAR (lack of remission): complete LAR- Patient failing to achieve remission after first three scheduled doses, or absence of remission 7 days after an infliximab infusion in a patient who had achieved remission after any previous infusion, and unresponsive to dose escalation or dose interval change, or relapse occurring &lt; 4 weeks after last infusion; partial LAR- Relapse 4 to 8 weeks after previous infusion, with requirement for dose escalation or shortening of infliximab schedule, and remission with change in dosing or interval</Description><Timeframe>76 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean trough level</Description><Timeframe>14 and 52 weeks</Timeframe></Measure><Measure><Description>Sustained steroid-free remission</Description><Timeframe>52 and 76 weeks</Timeframe></Measure><Measure><Description>Presence of ATI (antibodies to infliximab)</Description><Timeframe>52 weeks</Timeframe></Measure><Measure><Description>Corticosteroid free remission</Description><Timeframe>14 weeks</Timeframe></Measure><Measure><Description>Hospitalizations for LOR (loss of response) or failure to obtain remission</Description><Timeframe>Up to 76 weeks</Timeframe></Measure><Measure><Description>Medication associated adverse events</Description><Timeframe>Up to 76 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of the present study was to evaluate the best regimen for &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; monotherapy,
      and to evaluate if limited combination therapy with &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; and a immunomodulatorÂ  for the first 6
      months of therapy, in prior immunomodulator failures,  was superior to monotherapy with
      immunomodulator cessation from the second infusion, in preventing loss of remission to &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The investigators hypothesize that by combining thiopurines with &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; for the first 6 months,
      the investigators would detect a benefit . The investigators hypothesize that early cessation
      of a thiopurine  would increase the risk of LOR (Loss of response), decrease trough levels at
      14 weeks, and be associated with lower rates of corticosteroid free sustained remission by
      one year.
&lt;/para&gt;&lt;para&gt;It was a prospective, open-label, phase IV, randomized, controlled trial in pediatric patients with active Crohn's Disease (CD),
      defined by the porto criteria, despite &amp;gt; 10  weeks of  prior treatment with an
      immunomodulator (thiopurines), requiring &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;,   involving two arms, and intention to
      treat analysis after the  first infusion.&lt;/para&gt;&lt;para&gt;Arm 1: patients would receive  &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; 5 mg/kg for 76 weeks, continuing azathioprine or 6-mercaptopurine or methotrexate for 6 months from first infusion (immunomodulator therapy 26 weeks).&lt;br/&gt;Arm 2: patients would receive &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; 5 mg/kg induction for 76 weeks, discontinuing immunomodulator or 6-mercaptopurine or methotrexate on day of second infusion (after 14 days).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The study was terminated due to lack of budget and failure to reach milestones. &lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Israel"><Sites><Site><Name>The E. Wolfson.Medical Center</Name><Address1>Holon</Address1><Address3>58100</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Crohns disease</Disease><PatientSegments><PatientSegment><PatientSegment id="3403">Pediatric Crohns Disease Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3404">Subjects with Active Crohns Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01802593</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Crohns disease" id="6316"><Endpoint>Assessment of Remission</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Crohns disease" id="6316"><Endpoint>Assessment of Remission</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6321">Remission without corticosteroids</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Crohns disease" id="6406"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Crohns disease" id="6439"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6441">Drug related adverse event</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Crohns disease" id="6451"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6480">Assessment of anti-drug antibodies</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Crohns disease" id="45522"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Crohns disease" id="6466">Assessment of Hospitalization Rates</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Crohns disease" id="3161"><Criterion>Pediatric Crohn's Disease</Criterion></Inclusion><Inclusion disease="Crohns disease" id="3162"><Criterion>Subjects with Active Crohn's Disease</Criterion></Inclusion><Inclusion disease="Crohns disease" id="3199"><Criterion>Treatment Naive Subjects</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="3201">Biologic therapy naive subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Crohns disease" id="4370"><Criterion>Subjects with Extra-Intestinal Manifestations of Crohn's Disease</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4374">Subjects with hepatobiliary manifestations of Crohns disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4381"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4389"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4407"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4418"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4423"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4425">Abnormal hematological findings</SubCriterion><SubCriterion disease="Crohns disease" id="4426">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Crohns disease" id="4431"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Crohns disease" id="4442"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Crohns disease" id="4443">Study drug</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-12-24T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-05T12:40:17Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-04-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-12-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>